Human Longevity's $599 Whole Genome Sequencing Puts Clinical-Grade DNA Analysis in Everyone's Hands

For most of the past two decades, having your entire genome sequenced meant either joining a research study or paying tens of thousands of dollars at a specialist clinic. Human Longevity, Inc. (HLI) wants to end that era. The San Francisco-based precision health company has launched Genomics for All — clinical-grade whole genome sequencing at $599, with no clinic visit required and AI-interpreted results delivered through an app.

What $599 Actually Buys

The number matters, but so does what it covers. Genomics for All sequences all 6.4 billion base pairs of an individual's DNA at 30x clinical-grade depth — the coverage standard required for medically meaningful interpretation. That is a fundamentally different product from the consumer ancestry tests that currently dominate the market. Services such as 23andMe or AncestryDNA use SNP chip technology that analyses less than 0.02% of the genome, capturing common variants but missing the rarer mutations that often carry the highest clinical significance.

At 30x whole-genome depth, Genomics for All can identify inherited disease risk across more than 10,000 genetic variants, flag pharmacogenomic markers that affect how an individual responds to widely prescribed medications — including statins and GLP-1 receptor agonists — and screen for carrier status in hereditary conditions. The report also covers health-related traits spanning nutrition, metabolism, and exercise response.

The AI Re-Analysis Engine

The feature that distinguishes Genomics for All from a one-time test is its AI-powered re-analysis capability. Because an individual's genome does not change, HLI re-analyses stored genomic data on an ongoing basis as new research is published, new disease-gene associations are identified, and clinical guidelines are updated. When a new clinically relevant finding emerges from the scientific literature, HLI proactively alerts affected clients — the company says it typically does so within 24 hours of publication.

This turns what would otherwise be a static report into a continuously evolving health resource. A variant that has no established significance today may become actionable within two years as genome-wide association studies mature; clients who sequenced once are automatically in scope for that update without retesting.

Founder Legacy and Scientific Credibility

HLI was co-founded in 2013 by Dr. J. Craig Venter, who led the private effort to sequence the first human genome in 2001. That heritage is deliberate branding as much as biography. "Our founder Dr. Venter helped make it possible for humanity to read the human genome," said Wei-Wu He, Ph.D., Chairman and CEO. "With Genomics for All, we are continuing that vision by helping more people understand what their genome may mean for their long-term health."

The scientific advisory board includes Nobel laureates Dr. Geoffrey Hinton — known primarily for his work on deep learning — and Dr. Michael Levitt, the structural biologist, lending the AI interpretation layer considerable intellectual credibility. The company has invested approximately $600 million in research over its lifetime and worked with more than 10,000 clients across clinics in San Diego and San Francisco.

Context: A Broader AI-Longevity Platform

Genomics for All is positioned as the entry point into HLI's wider precision health ecosystem, which also includes executive health programmes combining advanced imaging, biomarker panels, and clinician-guided care. In May 2026, HLI launched Human Life Foundation Models, Inc. (HLFM) in partnership with Insilico Medicine, a clinical-stage generative AI biotech company. That multimillion-dollar collaboration is developing what the companies describe as the first large-scale AI foundation model dedicated to longevity science, drawing on HLI's multimodal clinical and genomic datasets to identify biological mechanisms of ageing and enable predictive healthcare.

Market Implications

The $599 price point lands well below the $1,000 threshold that the industry had long treated as a symbolic floor for clinical sequencing, and it arrives as GLP-1 drugs have sharpened consumer appetite for personalised, data-driven health management. For the health tech sector, the more consequential question is whether clinical-grade sequencing at consumer price points accelerates the shift from reactive to predictive medicine — and whether the AI interpretation layer can be validated rigorously enough to influence clinical decision-making at scale.

Genomics for All is available now at humanlongevity.com/genomics.